Financial Gravity Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Financial Gravity Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4	Closed	-$297	–	2492
2024 Q1	$297	Buy	+4	New	+$275	﹤0.01%	1533
2023 Q4	–	Hold	0	–	–	–	1271
2023 Q3	–	Sell	-63	Closed	-$3.67K	–	1078
2023 Q2	$91	Buy	+63	New	+$3.93K	﹤0.01%	1315
2023 Q1	–	Sell	-53	Closed	-$67	–	1721
2022 Q4	$67	Buy	+53	New	+$2.66K	﹤0.01%	1185

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Financial Gravity Asset Management's ITCI Position: Q2 2024 in Review

Financial Gravity Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2024, closing a stake of 4 shares — an estimated $297 sold.

Financial Gravity Asset Management first reported a position in ITCI in Q4 2022 and held it in 3 quarters. The position peaked at $297 in Q1 2024. 376 funds tracked by Wall St. Rank hold ITCI as of Q2 2024.

Financial Gravity Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2024 after selling out during the quarter.
Financial Gravity Asset Management sold 4 Intra-Cellular Therapies Inc. shares in Q2 2024, an estimated $297.
Financial Gravity Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q4 2022 and held it in 3 quarters.
Financial Gravity Asset Management's Intra-Cellular Therapies Inc. position peaked at $297 in Q1 2024.
376 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2024.

Based on Financial Gravity Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.